11.17.25 -- Quickly Match With Biologics CDMOs That Fit Your Needs

Sergie Letser, Deputy CCO, presents an overview of Nanoform’s novel large molecule nanoforming technology capabilities and current capacity.

This session provides a comprehensive overview of our biopharmaceutical contract manufacturing services for mammalian cell culture and microbial technologies.

Gain insight into our global manufacturing network, including information about the capabilities of each mammalian and microbial site within the network.

Accelerate your cancer therapy development with patient-derived organoids — high-fidelity models that enhance translational confidence, streamline discovery, and deliver treatments fast.

Speed up your biopharmaceutical program with a flexible, global manufacturing partner that minimizes risk, shortens timelines, and empowers seamless scaling from clinical to commercial production.

Michael Brotz provides an in-depth look at our Seattle site and the unique capabilities of the facility, including its single-use and stainless-steel capacity, new manufacturing lines, and more.

Our global facilities are purpose-built to guide you when your team is ready to scale, and to power your mRNA journey from early discovery to global commercialization.

Push your biotherapeutic program forward with a trusted global CDMO partner offering end-to-end development and manufacturing, supported by state-of-the-art facilities.

André Markmann, VP of Business Development, shares insights drawn from over 20 years of experience, more than 185 successful projects, and fully integrated microbial and mammalian facilities.

Partner with a U.S.-based, trusted CDMO large enough to support every stage of your program, yet agile enough to deliver the dedicated care your project deserves.

With proven expertise in process development, optimization, and CGMP manufacturing, Avid offers end-to-end CDMO solutions backed by flexible capacity designed to scale with program needs.

Propel your therapeutic antibody and complex protein development with advanced mammalian cell line platforms that move from DNA to RCB in just 10 weeks.

Leveraging decades of expertise, analytical capabilities, and regulatory knowledge, we deliver phase-appropriate solutions that streamline development, reduce risk, and accelerate timelines.

Discover a streamlined formulation development workflow for mAbs to provide a more efficient process, driving down costs and reducing timelines, without compromising on quality or safety.

This end-to-end solution covers every development stage, from early clone selection and small-scale manufacturing to process scale-up, large-scale production, and quality control.

We provide a range of solutions, including method development, validation, and transfer; PK and PD bioanalysis; ELISA and multiplex assays; bioassays; and immunogenicity testing.

Whether you're preparing for IND, scaling commercial operations, or navigating complex regulatory pathways, gain actionable strategies and updates to help you move forward with confidence.

MilliporeSigma and Simtra’s collaboration streamlines every stage — from bioconjugation and linker/payload supply to formulation development and final fill/finish.

Explore ThioBridge™ as an efficient site-specific conjugation technology to generate ADCs and other conjugate modalities, such as oligoconjugates and conjugates.

Our collaboration with MilliporeSigma encompasses every stage, including bioconjugation, linker and payload supplies, formulation development, and final fill/finish.